one of the benefits of going the reverse merger route is already having an existing shareholder base in place. the stock is here and is trading a decent amount of volume every day.
it's also worth keeping in mind that redman's interview just was released on some kind of Small Cap TV video thing. that might give you a clue about their intentions with their newly acquired OTC company. CEOs don't typically go making promotional type pieces like that for nothing.
New $AEPP CEO moving forward w/Oncolix R/M transition! We are now seeing evidence of what the CEO is actually doing behind the scenes while continuing to file the necessary paperwork for a successful transition into this empty shell. Once the market discovers what is really going on here, the share price will skyrocket! Anyone who hasn't taken the time to do the required DD, may very well lose patience and sell out for a loss, just prior to a major event to send the share price soaring imho. DD=$$$$$$ - Cheers!
BTW - This is what Oncolix is all about and what they are developing that has FDA ORPHAN DRUG STATUS while this stock trades at a ridiculous low price of around 3 CENTS PER SHARE right now!:
Oncolix, Inc. (Oncolix) is a clinical-stage biotechnology company
We are developing Prolanta™,a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer. This clinical trial began in 2016. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.
The FDA has also approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity.
News 
Market Data 
Discover 
